Complement Activation in Association with Markers of Neutrophil Extracellular Traps and Acute Myocardial Infarction in Stable Coronary Artery Disease
Autor: | Miriam Sjåstad Langseth, Karsten Engseth Kluge, Ingebjørg Seljeflot, Harald Arnesen, Theis Tønnessen, Ragnhild Helseth, A.A. Pettersen, Trine Baur Opstad |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
Adult
Male 0301 basic medicine medicine.medical_specialty Article Subject Immunology Myocardial Infarction Coronary Artery Disease 030204 cardiovascular system & hematology urologic and male genital diseases Extracellular Traps Gastroenterology C5a receptor Coronary artery disease 03 medical and health sciences 0302 clinical medicine Internal medicine Pathology medicine Clinical endpoint Humans RB1-214 Myocardial infarction Complement Activation Stroke Aged Peroxidase Aged 80 and over business.industry Unstable angina Cell Biology Neutrophil extracellular traps Middle Aged medicine.disease Complement system 030104 developmental biology Female business Biomarkers Research Article |
Zdroj: | Mediators of Inflammation, Vol 2020 (2020) Mediators of Inflammation |
ISSN: | 0962-9351 |
DOI: | 10.1155/2020/5080743 |
Popis: | Complement activation and neutrophil extracellular traps (NETs) have both been suggested to drive atherosclerotic plaque progression. Although experimental studies suggest interplay between these two innate immunity components, the relevance in patients with coronary artery disease (CAD) is unclear. The aim of this study was to assess associations between complement activation and NETs in patients with stable CAD and examine the role of complement activation on clinical outcome. Blood samples from a cohort of patients with angiographically verified stable CAD (n=1001) were analyzed by ELISA for the terminal complement complex (TCC) and by relative quantification for gene expression of the C5a receptor 1 (C5aR1) as markers of complement activation. As markers of NETs, dsDNA was analyzed by fluorescent nucleic acid stain and myeloperoxidase-DNA (MPO-DNA) by ELISA. Clinical outcome was defined as unstable angina, nonhemorrhagic stroke, acute myocardial infarction (MI), or death (n=106, whereof 36 MI). Levels of TCC and C5aR1 were not significantly correlated to dsDNA (TCC: r=−0.045, p=0.153; C5aR1: r=−0.060, p=0.434) or MPO-DNA (TCC: r=0.026, p=0.414; C5aR1: r=0.123, p=0.107). When dividing TCC and C5aR1 levels into quartiles (Q), levels of MPO-DNA differed significantly across quartiles (TCC: p=0.008, C5aR1: 0.049), while dsDNA did not (TCC: p=0.181, C5aR1: p=0.771). Patients with TCC levels in Q4 had significantly higher levels of MPO-DNA than Q1-3 (p=0.019), and C5aR1 levels in Q3-4 had significantly higher levels of MPO-DNA than Q1-2 (p=0.046). TCC levels did not differ between patients experiencing a clinical endpoint or not, but high levels were associated with increased risk of acute MI (OR. 1.97, 95% CI: 0.99-3.90, p=0.053) during two-year follow up, also when adjusted for relevant covariates. In conclusion, TCC and C5aR1 were moderately associated with the NET marker MPO-DNA, and TCC levels were related to the risk of future MI in this cohort of patients with stable CAD. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |